Accelerated FDA approval of the first-in-class CELMoD agent iberdomide (Zenbexus) offers a new oral option for adults with relapsed or refractory multiple myeloma.

MHT use linked to significantly lower odds of clinical dementia diagnoses and symptoms of memory/functional decline ...

Administration of dexamethasone eye drops reduces the proportion of preterm infants with prethreshold retinopathy of prematurity (ROP) progressing to type 1 ROP ...

HealthDay News — A new executive order calls for American children to be routinely immunized against 11 diseases instead of the 17 now recommended by federal health officials. President Donald Trump ...

Prespecified primary analyses showed significant improvement over placebo in patients aged 71 and older and those with a baseline 6MWD below 333 meters.

Thirteen conditional recommendations developed, including in relation to guiding therapy during exacerbations.

HealthDay News — A multistate outbreak of Salmonella infections has been linked to fresh jalapeño peppers imported from Sinaloa, Mexico, according to federal health officials.

FDA acceptance of the new drug application for lonafarnib marks a key milestone toward an oral treatment option for chronic hepatitis D.

The FTC alleges most consumers never get a consultation, instead, they are billed and enrolled in recurring subscription plans shortly after submitting the form.

The table below is a review of notable updates that occurred in July 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The 4C meningococcal B (MenB) vaccine confers modest protection against gonorrhea among adolescents, according to a study published online August 4 in Open Foru ...

Five major FDA Priority Review decisions are scheduled for September 2026, targeting rare genetic neurological conditions, FGFR2-mutated cholangiocarcinoma, and adolescent obstructive hypertrophic ...